Shire Settles Suit Against Teva Over Generic Intuniv

Shire Plc (SHP) settled a patent lawsuit against Teva Pharmaceutical Industries Ltd. (TEVA), paving the way for lower-cost generic copies of the drug Intuniv, used to treat attention deficit hyperactivity disorder.

Teva, the world’s largest generic-drug company, will get a license to market a version of the drug, Dublin-based Shire said today in a statement. The license takes effect once another generic-drug maker, Actavis Inc. (ACT), has sold the drug for six months starting in December 2014.

Shire sued Teva, based in Petach Tikva, Israel, in federal court in Wilmington, Delaware, in April 2010 alleging infringement of two patents for Intuniv. Shire previously settled with Parsippany, New Jersey-based Actavis over the patents. A trial of the litigation against Teva and Actavis was held in September.

The Teva settlement couldn’t immediately be confirmed in court papers. Shire said it submitted the agreements with Teva and Actavis to the Federal Trade Commission for review.

Teva officials didn’t immmediately respond to an e-mail seeking comment on Shire’s statement.

The case is Shire LLC v. Teva Pharmaceuticals USA Inc., 10-cv-00329, U.S. District Court, District of Delaware (Wilmington).

To contact the reporter on this story: Phil Milford in Wilmington, Delaware, at Pmilford @bloomberg.net.

To contact the editor responsible for this story: Michael Hytha at mhytha@bloomberg.net.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.